GLP-1 Drugs Linked to Small but Real Risk of Hair Loss, Study Finds

A new study published in The BMJ reveals that GLP-1 receptor agonists, such as semaglutide and tirzepatide, are associated with a significantly higher risk of hair loss compared to other diabetes medications, though the absolute risk remains low.

What the study found

Researchers at the University of Pennsylvania analysed medical records of roughly 12,000 people with type 2 diabetes who started a GLP-1 between 2019 and 2024, comparing them with patients taking SGLT-2 inhibitors or DPP-4 inhibitors. Key findings:

• GLP-1 users had a 37% higher risk of alopecia than SGLT-2 users and 68% higher risk than DPP-4 users Source: gizmodo.
• Only about 1.6% (200 of 12,000) of GLP-1 users developed hair loss during the study period Source: gizmodo.
• The heightened risk was primarily for non-scarring alopecia, where hair follicles remain intact, suggesting the loss is often reversible Source: gizmodo.

Why it happens

The study’s authors note that rapid weight loss and reduced calorie intake, common with GLP-1s, are known triggers of temporary hair shedding called telogen effluvium. Nutritional deficiencies (e.g., iron, zinc) and hormonal changes may also contribute Source: euronewsen. Further research is needed to clarify mechanisms and identify at-risk patients.

Despite the association, the absolute risk is low, and hair loss is not physically harmful. However, it may affect patients’ satisfaction and adherence to therapy Source: euronewsen.